A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Recruiting

• Conditions: Diabetes Mellitus; Hypertension

• Registration Number: NCT05970237
• Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-7-24
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 9000

Inclusion Criteria

Inclusion Criteria:<br><br> - Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are<br> scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.<br><br> - Those who voluntarily signed a written personal information agreement to participate<br> in this clinical study.<br><br> - Those able to understand this study, be cooperative in the execution of the study,<br> and participate in the study until its completion.<br><br>Exclusion Criteria:<br><br> - Patients with secondary hypertension: Secondary hypertension is not limited to the<br> following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal<br> artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease,<br> etc.)<br><br> - Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit<br> 1)<br><br> - Those who are expected to need insulin prescription during the study period<br><br> - Pregnant women, breast-feeding women

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Target blood pressure control rate;Target blood glucose achievement rate